Drugs / EXG110
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06819514 | Mar 2025 → Mar 2028 expected | Fabry disease | Guangzhou Jiayin Biotech Ltd | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06539624 | Oct 2024 → Apr 2027 expected | Fabry disease | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXG110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06539624 ↗ |
| Action | Activate | “significantly increases plasma AGA activity” NCT06539624 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “EXG110 is a recombinant adeno-associated virus (rAAV)” NCT06539624 ↗ |
| Route | Intravenous | “administered in a single dose by intravenous infusion” NCT06539624 ↗ |